A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of TFX05-01 in Participants With Advanced Malignancies
Latest Information Update: 17 Mar 2023
At a glance
- Drugs TFX 05 01 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Shenzhen Yangli Pharmaceutical Technology
- 30 Jun 2022 New trial record